Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake

Page 2 of 10

Page 2 of 10 – SEC Filing

CUSIP NO.
867328502
1
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Cormorant Global Healthcare Master Fund, LP
2
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [x]
3
SEC Use Only
4
Citizenship or Place of Organization.
Cayman Islands
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
5 Sole Voting Power
0 shares
6 Shared Voting Power
831,500 shares
Refer to Item 4 below.
7 Sole Dispositive Power
0 shares
8 Shared Dispositive Power
831,500 shares
Refer to Item 4 below.
9
Aggregate Amount Beneficially Owned by Each Reporting Person
831,500 shares
Refer to Item 4 below.
10
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ] N/A
11
Percent of Class Represented by Amount in Row (9)*
4.28%
Refer to Item 4 below.
12
Type of Reporting Person (See Instructions)
PN (Partnership)

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 2 of 10